Bayer Collaborates with Recursion to Fortify Digital Drug Discovery for Fibrotic Diseases
Shots:
- Recursion to receive $30M as up front- $50M as equity investment- ~$100M/ program as development and commercial milestones along with royalties on sales. The companies will work on more than ten programs
- Bayer will get an exclusive option to license novel therapies derived from the research activities
- The collaboration will deploy Recursion’s AI-guided drug discovery platform and Bayer’s small molecule compound library and expertise to discover and develop new treatments for fibrotic diseases of the lung- kidney- heart
Ref: PRNewswire | Image: Michigan Health Lab
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com